STEMI Clinical Trial - Empagliflozin for No-reflow Phenomenon in PCI for

Status Not yet recruiting

Clinical Trial Summary

Myocardial infarction remains, in our current era, a leading cause of morbidity and mortality both domestically and globally. A significant contributor to this issue is reperfusion injury, which enlarges the infarction, deteriorates ventricular function, leads to poorer outcomes, and currently has no specific treatment. Originally developed as an antidiabetic, empagliflozin has shown significant benefits in other organs and systems. Recent years have seen the demonstration of its cellular and vascular effects in animal models, potentially contributing to the reduction of reperfusion damage. However, no human studies have yet confirmed these effects. Consequently, this double-blind, randomized, parallel-arm clinical trial was designed to evaluate the effect of empagliflozin treatment, administered from the pre-intervention period through to 3 days post-intervention, on the incidence of the no-reflow phenomenon in patients with ST-segment elevation myocardial infarction (STEMI) undergoing coronary angioplasty compared to a placebo. Before entering the hemodynamics room, participants in the intervention group will receive a loading dose of 25 mg of empagliflozin or a placebo. In-hospital treatment will continue with 10 mg empagliflozin daily for 3 days for the intervention group, while the control group will receive a placebo. Patients will be monitored weekly during the first month and bi-weekly during the second and third months. The primary outcome will be the incidence of the no-reflow phenomenon, measured through the Thrombolysis in Myocardial infarction (TIMI) flow scale in the coronary angiography performed to treat the infarction. Secondary outcomes will include the reduction of ST segment on the electrocardiogram, troponin levels, differences in the longitudinal strain by echocardiogram, and infarct size by magnetic resonance imaging.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06342141
Study type	Interventional
Source	Instituto Nacional de Cardiologia Ignacio Chavez
Contact	Fabio Solis-Jimenez, MD, MSc
Phone	+525540838443
Email	fabiosolisjimenez@gmail.com
Status	Not yet recruiting
Phase	Phase 2
Start date	May 15, 2024
Completion date	March 15, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT02871622` - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM	N/A
Completed	`NCT01325116` - Delayed Educational Reminders in Acute Myocardial Infarction (MI)	N/A
Completed	`NCT01452139` - Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)	Phase 2/Phase 3
Completed	`NCT01625104` - Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI	N/A
Completed	`NCT04023266` - A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI	Phase 2
Completed	`NCT02170103` - Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial	N/A
Completed	`NCT03103620` - Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
Not yet recruiting	`NCT05975567` - Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
Enrolling by invitation	`NCT03328156` - Erectile Dysfunction After Percutaneous Coronary Intervention Versus the Thrombolytic Therapy in Acute ST Elevation Myocardial Infarction	N/A
Completed	`NCT04017169` - No Reflow Phenomenon Incidence and Predictors
Completed	`NCT03470441` - A Study of Acute Myocardial Infarction Using FDY-5301	Phase 2
Active, not recruiting	`NCT01433627` - Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX	Phase 3
Completed	`NCT01197742` - Sweetheart-Register: Risk Management of Diabetics With Acute Myocardial Infarction	N/A
Terminated	`NCT03439150` - Resistance STEMI Study	N/A
Recruiting	`NCT03998319` - A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.	Phase 3
Not yet recruiting	`NCT05974930` - Intravascular ULTRAsound-Guided PCI in Patients With ST-Elevation Myocardial Infarction
Active, not recruiting	`NCT03102723` - Platelet Inhibition to Target Reperfusion Injury	Phase 2
Completed	`NCT03930589` - Remote Ischemic Conditioning in STEMI to Decrease Infarct Size	N/A
Not yet recruiting	`NCT04912167` - The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction	Phase 3
Completed	`NCT02942550` - Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Empagliflozin for No-reflow Phenomenon in PCI for STEMI — EMPA-PCI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms